Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Nautilus Biotechnology (NAUT) EBIAT (2020 - 2026)

Nautilus Biotechnology has reported EBIAT over the past 7 years, most recently at -$14.7 million for Q1 2026.

  • Quarterly results put EBIAT at -$14.7 million for Q1 2026, up 11.53% from a year ago — trailing twelve months through Mar 2026 was -$57.1 million (up 16.86% YoY), and the annual figure for FY2025 was -$59.0 million, up 16.64%.
  • EBIAT reached -$14.7 million in Q1 2026 per NAUT's latest filing, down from -$13.8 million in the prior quarter.
  • Across five years, EBIAT topped out at -$13.4 million in Q4 2022 and bottomed at -$18.7 million in Q1 2024.
  • Median EBIAT over the past 5 years was -$15.8 million (2022), compared with a mean of -$15.7 million.
  • The largest annual shift saw EBIAT tumbled 87.45% in 2022 before it grew 21.67% in 2025.
  • Over 5 years, EBIAT stood at -$13.4 million in 2022, then fell by 26.96% to -$17.0 million in 2023, then fell by 3.35% to -$17.6 million in 2024, then rose by 21.67% to -$13.8 million in 2025, then decreased by 6.65% to -$14.7 million in 2026.
  • Business Quant data shows EBIAT for NAUT at -$14.7 million in Q1 2026, -$13.8 million in Q4 2025, and -$13.6 million in Q3 2025.